The aim of this study was to examine the prevalence of Helicobacter pylori infection and the associated gastroduodenal lesions in peritoneal dialysis patients. Ninety-eight patients with dyspeptic complaints were included in the study. They were divided into two groups; group 1 consisted of 48 patients with end-stage renal disease (ESRD) on PD and group 2 (control) of 50 patients without renal disease. All patients were subjected to upper gastrointestinal endoscopies, and gastric biopsies were obtained for histological evidence of H.pylori infection. Anti-H.pylori IgG antibodies were tested in the PD patients using the ELISA test. The mean age of both groups was similar. Twenty-three (47.9%) of the 48 patients on PD and 25 (50.0 %) of the 50 non-renal disease patients were positive for H.pylori infection. There was no significant difference in H.pylori prevalence between the two groups (P>0.05). No correlation was found between H.pylori infection and age, sex, primary disease, or type (CAPD or APD). However, prevalence was significantly higher (30.4% vs 17.4%, Plt;0.001) in patients who were on PD for less than 24 months. False positive serology for H.pylori in the absence of positive histology was found in 7 out of the 25 negative cases (28.0 %) in the dialysis group. The prevalence of duodenal ulcers was significantly higher in H.pylori positive than in H.pylori negative ESRD patients on PD (18.8% vs 8.3%, P<0.05). Gastroesophageal reflux disease (GERD) was seen in 21 (43.8%) patients in group 1 and in 8 (16%) cases in group 2 (P<0.01). GERD was, however, significantly lower in H.pylori positive patients in both groups (12.5% vs 31.3% in group 1 and 4% vs 12% in group 2, Plt;0.001 and P<0.01, respectively). In conclusion, long-term PD seems to decrease the prevalence of H.pylori infection. Testing H.pylori antibodies lacks specificity for diagnosing active H.pylori infection in PD patients. H.pylori infection in patients on PD is associated with increased risk of gastroduodenal lesions and decreased prevalence of GERD.
Al-QurainA., SattiM.B., Al-HamdanA.Pattern of upper gastrointestinal disease in the Eastern Province of Saudi Arabia: Endoscopic evaluation of 2982 patients.Trop Geog Med1991; 43: 203–8.
4.
MohammadA.E., Al-KarawiM.A., Al-JumaA.A.Helicobacter pylori: prevalence in 352 consecutive patients with dyspepsia.Ann Saudi Med1994; 14: 134–5.
5.
BradyCE3rd, HadfieldT.L., HyattJ.R.Acid secretion and serum gastrin levels in individuals with Campylobacter pylori.Gastroenterol1988; 94: 923–7.
6.
KangJ.Y., HoK.Y., YeohK.G.Peptic ulcer and gastritis in uremia, with particular reference to the effect of Helicobacter pylori infection.J Gastroenterol Hepatol1999; 14: 771–8.
7.
LuzzaF., ImenoM., MalettaM.Helicobacter pylori-specific IgG in chronic hemodialysis patients: relationship of hypergastrinemia to positive serology.Nephrol Dial Transplant1996; 11: 120–4.
8.
DongR., GuoZ Y.Gastrointestinal symptoms in patients undergoing peritoneal dialysis: Multivariate analysis of correlated factors.World J Gastroenterol2010; 16: 1812–7.
9.
ShoushaS., ArnaoutA.H., AbbasS.H.Antral Helicobacter pylori in patients with chronic renal failure.J Clin Path1990; 43: 397–9.
10.
SmithJ.T., PounderR.E., NwokoloC.U.Inappropriate hypergastrinemia in asymptomatic healthy subjects infected with Helicobacter pylori.Gut1990; 31: 522–5.
11.
El-OmarE., PenmanI., DorrianC.A.Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.Gut1993; 34: 1060–5.
12.
YildizA., BesisikF., AkkayaV.Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients.Clin Transplantation1999; 13: 13–6.
13.
KimH., ParkC., JangW.I.The gastric juice urea and ammonia levels in patients with Campylobacter pylori.Am J Clin Pathol1990; 94: 187–91.
MoriyamaT., MatsumotoT., HirakawaK.Helicobacter pylori status and esophagogastroduodenal lesions in patients with end-stage renal failure on maintenance hemodialysis.J Gastroenterol2010; 45: 515–22.
16.
GladziwaU., HaaseG., HandtS.Prevalence of Helicobacter pylori in patients with chronic renal failure.Nephrol Dial Transplant1993; 8: 301–6.
17.
DavenportA., ShallcrossT.M., CrabtreeJ.E.Prevalence of Helicobacter pylori in patients with end stage renal disease and renal transplant recipients.Nephron1991; 59: 597–601.
18.
TeenanR.P., BurgayneM., BrownI.L.Helicobacter pylori in renal transplant recipients.Transplantation1993; 56: 100–4.
19.
AthertonJ.C., BlaserM.J.Helicobacter infections. In: FauciAS, BraunwaldE, IsselbacherKJ, WilsonJD, MartinJB, KasperDL, HauserSL, LongoDL (eds.) Harrison's Principles of Internal Medicine (14th ed.) McGraw-Hill, New York, NY, 1998, pp 931–43.
20.
LinJ.T., WangJ.T., WuM.S.Seroprevalence study of Helicobacter pylori infection in patients with gastroduodenal disease.J Formos Med Assoc1994; 93: 122–7.
21.
Munoz de BustilloE., Sanchez TomeroJ.A., SanzJ.C.Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients.Nephron1998; 79: 55–60.
22.
Di GiorgioP., RivelliniG., D'AlessioL.The influence of high blood levels of urea on the presence of Campylobacter pylori in the stomach: A clinical study.Ital J Gastroenterol1990; 22: 64–5.
23.
Ala-KailaK., VaajalahtiP., KarvonenA.L.Gastric Helicobacter and upper gastrointestinal symptoms in chronic renal failure.Ann Med1991; 23: 403–6.
24.
MutoS., AsanoY., HosodaS.Hypochlorhydria and hypergastrinemia and their association with gastrointestinal bleeding in undialyzed and hemodialyzed patients.Nephron1988; 50: 10–3.
25.
AkmalM., SawelsonS., KarubianF.The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure, or receiving dialytic therapy.Clin Nephrol1994; 42: 198–202.
26.
KaoC.H., HsuY.H., WangS.J.Delayed gastric emptying and Helicobacter pylori infection in patients with chronic renal failure.Eur J Nucl Med1995; 22: 1282–5.
27.
WeeA., KangJ.Y., HoM.S.Gastroduodenal mucosa in uremia: Endoscopic and histological correlation and prevalence of Helicobacter like organisms.Gut1990; 31: 1093–6.
28.
JaspersonD., FassbinderW., HeinkeleP.Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal function.J Gastroenterol1995; 30: 585–8.
29.
BerstadA., AlexanderB., WebergR.Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with non-ulcer dyspepsia and erosive prepyloric changes.Gastroenterol1988; 95: 619–24.
30.
FabriziT., MartinP., DixitV.Epidemiology of Helicobacter pylori in chronic hemodialysis patients using the new RIB-ATM H.pylori SIA.Nephrol Dial Transplant1999; 14: 1929–33.
31.
SimenhoffM.I., SaukonenJ.J., BurkeJ.F.Bacterial populations of the small intestine in uremia.Nephron1978; 22: 63–8.
32.
HarumaK., OkamotoS., KawaguchiH.Reduced incidence of Helicobacter pylori in young Japanese persons between the 1970s and the 1990s.J Clin Gastroenterol1997; 25: 583–6.
33.
ConzP., ChiaramonteS., RoncoC.Campylobacter pylori in uremic dialyzed patients.Nephron1989; 53: 90–4.
34.
Von WuffenH.An assessment of serological tests for the detection of Helicobacter pylori.Eur J Clin Microbiol Infect Dis1992; 11: 577–82.
35.
BergeyB., MarchildonP., PeacockJ.What is the role of serology in assessing Helicobacter pylori eradication?Aliment Pharmacol Ther2003; 18: 635–9.
36.
VairaD., MalfertheinerP., MegraudF.Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group.Am J Gastroenterol2000; 95: 925–9.
37.
Van de WouwB.A.M., de BoerW.A., JanszA.R.Serodiagnosis of Helicobacter pylori infection in the Netherlands: an evaluation of a commercially available ELISA IgG. Neth. J.Med1995; 47: 272–7.
38.
Van de WouwB.A., de BoerW.A., JanszA.R.Comparison of three commercially available enzyme-linked immunosorbent assays and biopsy-dependent diagnosis for detecting Helicobacter pylori infection.J Clin Microbiol1996; 34: 94–7.
39.
MarchildonP., BalabanD.H., SueM.Usefulness of serological IgG antibody determination for confirming eradication of Helicobacter pylori infection.Am J Gastroenterol1999; 94: 2105–8.
ChoY.S., ChoiM.G., JeongJ.J.Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Asan-si, Korea.Am J Gastroenterol2005; 100: 747–53.
42.
MutoS., MurayamaN., AsanoY.Hypergastrinemia and achlorhydria in chronic renal failure.Nephron1985; 40: 143–8.
43.
WatanabeH., HiraishiH., IshidaM.Pathophysiology of gastric acid secretion in patients with chronic renal failure: influence of Helicobacter pylori infection.J Intern Med2003; 254: 439–46.
44.
StridH., FjellA., SimrenM.Impact of dialysis on gastresophageal reflux, dyspepsia and proton pump inhibitor treatment in patients with chronic renal failure.Eur J Gastroenterol Hepatol2009; 21: 137–42.
El-SeragH.B., SonnenbergA., JamalM.M.Corpus gastritis is protective against reflux oesophagitis.Gut1999; 45: 181–5.
49.
CekinA.H., BoyacrogluS., GursoyM.Gastroesophageal reflux disease in chronic renal failure patients with upper GI symptoms: Multivariate analysis of pathogenetic factors.Am J Gastrointerol2002; 97: 1352–56.
50.
MalfertheinerP., MegraudF., O'MorainC.Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report.Gut2007; 56: 772–81.
51.
SarnelliG., IeradiE., GrassoR.Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection.Dig Liver Dis2003; 35: 151–6.
52.
LitjensN.H., HuismanM., van den DorpelM.Impaired immune responses and antigen-specific memory CD+4 T cells in hemodialysis patients.J Am Soc Nephrol2008; 19: 1483–90.
53.
KrishnamurthyG., KherV., NaikS.Low response to HBs Ag vaccine in chronic renal failure patients is not due to intrinsic defect of B cells.Scand J Urol Nephrol2002; 36: 377–82.
54.
KurzP., KohlerH., MeuerS.Impaired cellular immune responses in chronic renal failure: Evidence for a T cell defect.Kidney Int1986; 29: 1209–14.
55.
RaskaKJr., RaskovaJ., SheaS.M.T cell subsets and cellular immunity in end-stage renal disease.Am J Med1983; 75: 734–40.
56.
LibettaC., RampiroT., Dal CantonA.Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients.Am J Kidney Dis2001; 38: 286–95.
57.
SesterU., SesterM., HaukM.T cell activation follows Th1 rather than Th2 pattern in hemodialysis patients.Nephrol Dial Transplant2000; 15: 1217–23.
58.
AbdulrahmanI.S., Al-QuorainA.A.Prevalence of Gastroesophageal reflux disease and its association with Helicobacter pylori infection in chronic renal failure patients and in renal transplant recipients.S J Gastroenterol2008; 14: 183–6.
59.
He HingerW.C., YaoJ.D., AlvarezS.A randomized, prospective double-blinded evaluation of selective bowel decontamination in liver transplantation.Transplantation2002; 73: 1904–9.
60.
SteffenR., ReinhartzO., BlumhardtG.Bacterial and fungal colonization and infections using oral selective bowel decontamination in orthotropic liver transplantation.Transplant Int1994; 7: 101–8.
61.
KaulH., GirndtM., SesterU.Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease.Am J Kidney Dis2000; 35: 611–6.
